Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,444.25
(
0.58%
)
US TECH 100
28,677.81
(
0.31%
)
Dow Jones
49,693.20
(
-0.14%
)
Brent Oil
103.32
(
-0.36%
)
Bitcoin
79,566.67
(
0.36%
)
News Focus
News Focus
Post# of 257556
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122977
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: alertmeipp post# 99355

Friday, 07/23/2010 11:29:40 AM

Friday, July 23, 2010 11:29:40 AM

Post# of 257556
As I've posted on numerous occasions, Copaxone is a very much easier drug to characterize than Lovenox. If the FDA was willing to approve MNTA's generic Lovenox, MNTA's obtaining approval for generic Copaxone in due course is close to a fait accompli, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today